Dr. Reddy's Laboratories (RDY) Competitors

$12.81 +0.33 (+2.64%)

Closing price 03:59 PM Eastern

Extended Trading

$12.82 +0.02 (+0.12%)

As of 07:30 PM Eastern

RDY vs. ONC, RPRX, ZTS, VTRS, and NBIX

Should you buy Dr. Reddy's Laboratories stock or one of its competitors? Dr. Reddy's Laboratories's main competitors and comparable companies include BeOne Medicines (ONC), Royalty Pharma (RPRX), Zoetis (ZTS), Viatris (VTRS), and Neurocrine Biosciences (NBIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

BeOne Medicines currently has a consensus price target of $404.93, suggesting a potential upside of 14.23%. Dr. Reddy's Laboratories has a consensus price target of $1,450.00, suggesting a potential upside of 11,523.25%. Given Dr. Reddy's Laboratories' higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BeOne Medicines has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

In the previous week, BeOne Medicines had 13 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 13 mentions for BeOne Medicines and 0 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.84 beat BeOne Medicines' score of 0.29 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Overall Sentiment
BeOne Medicines	Neutral
Dr. Reddy's Laboratories	Positive

BeOne Medicines has a net margin of 10.70% compared to Dr. Reddy's Laboratories' net margin of 10.15%. BeOne Medicines' return on equity of 14.23% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Dr. Reddy's Laboratories has lower revenue, but higher earnings than BeOne Medicines. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.28	$286.93M	$5.68	62.41
Dr. Reddy's Laboratories	$3.58B	2.91	$456M	$0.44	28.35

Summary

BeOne Medicines beats Dr. Reddy's Laboratories on 14 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

In the previous week, Royalty Pharma had 8 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 8 mentions for Royalty Pharma and 0 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.84 beat Royalty Pharma's score of 0.73 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Overall Sentiment
Royalty Pharma	Positive
Dr. Reddy's Laboratories	Positive

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Royalty Pharma has higher earnings, but lower revenue than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.54B	12.91	$770.95M	$1.45	39.26
Dr. Reddy's Laboratories	$3.58B	2.91	$456M	$0.44	28.35

Royalty Pharma has a net margin of 32.14% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Royalty Pharma's return on equity of 30.01% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.7%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has raised its dividend for 5 consecutive years. Royalty Pharma is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Royalty Pharma has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Royalty Pharma currently has a consensus price target of $61.57, suggesting a potential upside of 8.15%. Dr. Reddy's Laboratories has a consensus price target of $1,450.00, suggesting a potential upside of 11,523.25%. Given Dr. Reddy's Laboratories' higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Royalty Pharma beats Dr. Reddy's Laboratories on 15 of the 19 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Zoetis?

Dr. Reddy's Laboratories (NYSE:RDY) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Zoetis has a net margin of 27.49% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Zoetis' return on equity of 74.89% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Zoetis	27.49%	74.89%	18.59%

Dr. Reddy's Laboratories presently has a consensus price target of $1,450.00, suggesting a potential upside of 11,523.25%. Zoetis has a consensus price target of $101.08, suggesting a potential upside of 35.18%. Given Dr. Reddy's Laboratories' higher probable upside, research analysts plainly believe Dr. Reddy's Laboratories is more favorable than Zoetis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

In the previous week, Zoetis had 8 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 8 mentions for Zoetis and 0 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.84 beat Zoetis' score of 0.58 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Positive
Zoetis	Positive

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.8%. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Zoetis pays out 34.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Zoetis has higher revenue and earnings than Dr. Reddy's Laboratories. Zoetis is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.91	$456M	$0.44	28.35
Zoetis	$9.47B	3.26	$2.67B	$6.07	12.32

Summary

Zoetis beats Dr. Reddy's Laboratories on 14 of the 19 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Viatris?

Dr. Reddy's Laboratories (NYSE:RDY) and Viatris (NASDAQ:VTRS) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Viatris	-2.79%	20.02%	8.02%

Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Viatris pays out -133.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Viatris has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Dr. Reddy's Laboratories has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.91	$456M	$0.44	28.35
Viatris	$14.30B	1.42	-$3.51B	-$0.36	N/A

In the previous week, Viatris had 13 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 13 mentions for Viatris and 0 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.84 beat Viatris' score of 0.30 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Positive
Viatris	Neutral

Dr. Reddy's Laboratories currently has a consensus target price of $1,450.00, indicating a potential upside of 11,523.25%. Viatris has a consensus target price of $20.50, indicating a potential upside of 16.21%. Given Dr. Reddy's Laboratories' higher probable upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Viatris	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Viatris beats Dr. Reddy's Laboratories on 10 of the 18 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Neurocrine Biosciences?

Dr. Reddy's Laboratories (NYSE:RDY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

In the previous week, Neurocrine Biosciences had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Neurocrine Biosciences and 0 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.84 beat Neurocrine Biosciences' score of 0.78 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Positive
Neurocrine Biosciences	Positive

Dr. Reddy's Laboratories currently has a consensus target price of $1,450.00, indicating a potential upside of 11,523.25%. Neurocrine Biosciences has a consensus target price of $202.05, indicating a potential upside of 41.85%. Given Dr. Reddy's Laboratories' higher possible upside, research analysts plainly believe Dr. Reddy's Laboratories is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.83

Dr. Reddy's Laboratories has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Neurocrine Biosciences has lower revenue, but higher earnings than Dr. Reddy's Laboratories. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.91	$456M	$0.44	28.35
Neurocrine Biosciences	$2.86B	5.06	$478.60M	$6.82	20.89

Neurocrine Biosciences has a net margin of 20.91% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Neurocrine Biosciences' return on equity of 22.43% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Neurocrine Biosciences	20.91%	22.43%	15.64%

Summary

Neurocrine Biosciences beats Dr. Reddy's Laboratories on 13 of the 17 factors compared between the two stocks.

Get Dr. Reddy's Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RDY vs. The Competition

Export

Metric	Dr. Reddy's Laboratories	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$10.42B	$12.38B	$7.26B	$23.07B
Dividend Yield	0.51%	2.64%	2.53%	3.72%
P/E Ratio	29.11	800.12	275.65	28.54
Price / Sales	2.99	830.33	622.62	95.79
Price / Cash	14.73	15.28	27.30	19.30
Price / Book	2.64	9.01	10.85	4.71
Net Income	$456M	$2.83B	$3.50B	$1.07B
7 Day Performance	3.93%	-1.97%	-2.14%	-0.18%
1 Month Performance	7.58%	-4.68%	-4.88%	-3.59%
1 Year Performance	-10.68%	-4.95%	6.00%	9.32%

Dr. Reddy's Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RDY Dr. Reddy's Laboratories	4.0518 of 5 stars	$12.81 +2.6%	$732.40 +5,617.9%	-13.0%	$10.42B	$3.58B	29.11	27,527	Analyst Upgrade
ONC BeOne Medicines	3.9645 of 5 stars	$340.87 -6.4%	$404.93 +18.8%	+10.7%	$37.43B	$5.34B	60.02	12,000
RPRX Royalty Pharma	3.9728 of 5 stars	$55.36 -2.5%	$61.57 +11.2%	+58.1%	$31.82B	$2.38B	38.16	100
ZTS Zoetis	4.4323 of 5 stars	$72.22 +0.9%	$101.08 +40.0%	-47.0%	$29.84B	$9.47B	11.90	14,500	Dividend Announcement
VTRS Viatris	3.2412 of 5 stars	$17.13 -2.0%	$20.50 +19.7%	+81.1%	$19.73B	$14.30B	N/A	30,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RDY) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dr. Reddy's Laboratories (RDY) Competitors

RDY vs. ONC, RPRX, ZTS, VTRS, and NBIX

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

Summary

How does Dr. Reddy's Laboratories compare to Royalty Pharma?

Summary

How does Dr. Reddy's Laboratories compare to Zoetis?

Summary

How does Dr. Reddy's Laboratories compare to Viatris?

Summary

How does Dr. Reddy's Laboratories compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDY vs. The Competition

Dr. Reddy's Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dr. Reddy's Laboratories (RDY) Competitors

RDY vs. ONC, RPRX, ZTS, VTRS, and NBIX

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

Do analysts rate ONC or RDY?

Do insiders and institutionals have more ownership in ONC or RDY?

Which has more risk & volatility, ONC or RDY?

Does the media prefer ONC or RDY?

Is ONC or RDY more profitable?

Which has stronger valuation and earnings, ONC or RDY?

Summary

How does Dr. Reddy's Laboratories compare to Royalty Pharma?

Does the media prefer RPRX or RDY?

Do insiders and institutionals hold more shares of RPRX or RDY?

Which has better valuation & earnings, RPRX or RDY?

Is RPRX or RDY more profitable?

Is RPRX or RDY a better dividend stock?

Which has more risk & volatility, RPRX or RDY?

Do analysts rate RPRX or RDY?

Summary

How does Dr. Reddy's Laboratories compare to Zoetis?

Is RDY or ZTS more profitable?

Do analysts prefer RDY or ZTS?

Does the media prefer RDY or ZTS?

Do institutionals & insiders have more ownership in RDY or ZTS?

Which has more risk and volatility, RDY or ZTS?

Is RDY or ZTS a better dividend stock?

Which has better earnings and valuation, RDY or ZTS?

Summary

How does Dr. Reddy's Laboratories compare to Viatris?

Is RDY or VTRS more profitable?

Is RDY or VTRS a better dividend stock?

Do institutionals & insiders have more ownership in RDY or VTRS?

Which has more volatility & risk, RDY or VTRS?

Which has better valuation & earnings, RDY or VTRS?

Does the media prefer RDY or VTRS?

Do analysts prefer RDY or VTRS?

Summary

How does Dr. Reddy's Laboratories compare to Neurocrine Biosciences?

Does the media prefer RDY or NBIX?

Do analysts prefer RDY or NBIX?

Which has more volatility and risk, RDY or NBIX?

Do insiders & institutionals hold more shares of RDY or NBIX?

Which has preferable valuation and earnings, RDY or NBIX?

Is RDY or NBIX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RDY vs. The Competition

Dr. Reddy's Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools